Friday, July 10, 2026

Drug profile · INN

amlodipine maleate

amlodipine maleate (AMVAZ) is a voltage-gated l-type calcium channel blocker. Route of administration: oral. Current US regulatory status: approved.

FDA: approved
US status approved
Patents linked 0
Pipeline programs 0
News articles 0
Drug details — amlodipine maleate
US status
approved
Class
Route
ORAL
Patents
0
Programs
0
Data quality
0.84

Quick answer

amlodipine maleate (AMVAZ) is a voltage-gated l-type calcium channel blocker. Route of administration: oral. Current US regulatory status: approved.

Key facts

INN amlodipine maleate
Brand AMVAZ
Mechanism Voltage-gated L-type calcium channel blocker
Target Voltage-gated L-type calcium channel
Route ORAL
Formulation CAPSULE

Mechanism of action

Voltage-gated L-type calcium channel blocker

Primary target: Voltage-gated L-type calcium channel

Approval history

Authority Status Date
FDA approved

Related & competitor drugs

  1. amlodipine benzoate Voltage-gated L-type calcium channel blocker
  2. amlodipine besylate Voltage-gated L-type calcium channel blocker
  3. diltiazem hydrochloride Voltage-gated L-type calcium channel blocker
  4. isradipine Voltage-gated L-type calcium channel blocker
  5. nicardipine hydrochloride Voltage-gated L-type calcium channel blocker
  6. nifedipine Voltage-gated L-type calcium channel blocker

Frequently asked questions

What is amlodipine maleate?

amlodipine maleate (AMVAZ) is a voltage-gated l-type calcium channel blocker. Route of administration: oral. Current US regulatory status: approved.

What is the brand name for amlodipine maleate?

AMVAZ is a marketed brand name for amlodipine maleate. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of amlodipine maleate?

amlodipine maleate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.